Cure Today2h
Opdivo Plus Chemo Shows 5-Year Efficacy in Gastric, GEJ and Esophageal Cancer
Among patients with advanced gastric and GEJ cancer, or esophageal adenocarcinoma, treatment with first-line Opdivo and chemo demonstrated deep responses.
Targeted Oncology4h
5-Year Update Sustains Nivolumab/Chemo Efficacy in Frontline Gastric/GEJ/Esophageal Cancer
CheckMate 649 trial showed sustained efficacy with frontline nivolumab plus chemotherapy vs chemotherapy alone in patients with gastric cancers.
Cure Today9h
The FDA Accepts a BLA for RP1 Plus Opdivo in Advanced Melanoma
The FDA has accepted a BLA for treatment with RP1 in combination with Opdivo for patients with advanced melanoma who have progressed on prior therapy.
Stocktwits on MSN12h
Exicure Stock Soars Over 25% On Acquisition Of GPCR Therapeutics’ U.S. Unit: Retail Chatter Spikes
Shares of Exicure Inc. surged more than 25% on Thursday, reaching levels last seen over three weeks ago, following the ...